meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Phase 3 Recruiting 20 enrolled University Health Network, Toronto

NaSingle-groupOpen-labelTreatment

Summary

The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).

Timeline

Start: 2024-09-01
Primary completion: 2027-05-01
Completion: 2027-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Empagliflozin	Small molecule	25 mg	Oral

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Summary

Timeline

Drugs

Indications